Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2026 09:15 ET | Source: GRI Bio, Inc.

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc....
May 15, 2026 08:30 ET | Source: Jyong Biotech Ltd.

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development...
May 12, 2026 09:30 ET | Source: Moleculin Biotech, Inc.

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal...
May 07, 2026 08:05 ET | Source: Scienture Holdings, Inc.

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatment Financing also...
April 22, 2026 09:00 ET | Source: Eleos Health

Eleos Expands AI Agents Across the Full Care Journey

DENVER and BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Eleos, the system of action for community-based care, today announced the expansion of its platform with new AI agents across clinical insights,...
April 16, 2026 09:20 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC...
April 08, 2026 10:00 ET | Source: Foundation for Opioid Response Efforts

FORE Awards Grant to Advance New Payment Models for Opioid Use Disorder Treatment

New York, April 08, 2026 (GLOBE NEWSWIRE) -- The Foundation for Opioid Response Efforts (FORE) has awarded a $473,675 grant to The Brookings Institution to develop new payment models that...
April 08, 2026 09:00 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy

Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high...
April 08, 2026 08:30 ET | Source: GRI Bio, Inc.

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA,...
March 23, 2026 08:31 ET | Source: Moleculin Biotech, Inc.

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40% Remission Rate Across Difficult-to-Treat...